This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-27 and is reviewed periodically as new material appears.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
| Property | Value | Notes |
|---|---|---|
| Purity method | Reversed-phase HPLC | C18 column, UV detection at 214 nm |
| Identity method | Mass spectrometry | Electrospray or MALDI-TOF |
| Solubility | Soluble in water and DMSO | Dissolution may require brief mixing |
| Storage temperature | -20 °C or lower | Desiccated and protected from light |
| Counterion form | Trifluoroacetate or acetate | Affects measured peptide content |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
== External links == The MEROPS online database for peptidases and their inhibitors: I35.001 Overview of all the structural information available in the PDB for UniProt: P01033 (Metalloproteinase inhibitor 1) at the PDBe-KB.
The great chain of being (from Latin scala naturae 'ladder of being') is a hierarchical structure of all matter and life, thought by the medieval Islamic world and medieval Christianity to have been decreed by God. The chain begins with God and descends through angels, humans, animals and plants to minerals. The great chain of being is a concept derived from Plato, Aristotle (in his Historia Animalium), Plotinus and Proclus. Further developed during the Middle Ages, it reached full expression in early modern Neoplatonism.
== Limitations of mechanical micronization == Although mechanical micronization is the most widely used industrial technique, the high specific energy delivered by milling can alter the solid-state properties of the active beyond simple size reduction. The most extensively documented consequence is partial conversion of crystalline material to the amorphous state at the newly created particle surfaces. Because the amorphous state has higher free energy, greater hygroscopicity, and faster dissolution than the parent crystal, surface amorphization can shift dissolution behaviour, accelerate moisture uptake, and recrystallize uncontrollably during storage — altering the very properties micronization was performed to achieve. Mechanical stress can also drive polymorphic conversion between crystalline forms or induce conversion from anhydrous to hydrated phases (and vice versa). The thermodynamic driving force is provided by the cumulative mechanical energy absorbed by the lattice; in some cases the milled product passes through an amorphous intermediate before recrystallizing into a different polymorph than the starting material. Because different polymorphs and hydrates have different solubility, dissolution rate, and bioavailability, mill-induced polymorphic conversion is a critical quality attribute that must be monitored by techniques such as X-ray powder diffraction, differential scanning calorimetry, and Raman spectroscopy.
Sources: en.wikipedia.org
=== Evolutionary adaptation === The thalassemia trait may confer a degree of protection against malaria, which is historically endemic in the regions where the trait is common. This is thought to confer a selective survival advantage on carriers (known as heterozygous advantage), thus perpetuating the mutation. In that respect, the various thalassemias resemble other genetic disorders affecting hemoglobin, such as sickle-cell disease or Hemoglobin C disease.
=== In fiction === Jonathan Evison's novel, The Revised Fundamentals of Caregiving, published in 2012, depicted a young man affected by the disease. In 2016, Netflix released The Fundamentals of Caring, a film based on the novel.
==== 1000–1099 ==== Export of Goods (Control) (Amendment) Order 1993 (S.I. 1993/1020) Foreign Satellite Service Proscription Order 1993 (S.I. 1993/1024) Social Security (Consequential Provisions) Act 1992 Appointed Day Order 1993 (S.I. 1993/1025) Cranfield Airport (Designation) (Detention and Sale of Aircraft) Order 1993 (S.I. 1993/1026) Weymouth and Portland Harbour Revision Order 1993 (S.I. 1993/1027) Town and Country Planning (General Permitted Development) (Scotland) Amendment Order 1993 (S.I. 1993/1036) Gaming Act (Variation of Monetary Limits) (Scotland) Order 1993 (S.I. 1993/1037) Town and Country Planning (Use Classes) (Scotland) Amendment Order 1993 (S.I. 1993/1038) Town and Country Planning (General S.I. 1993/1039) Gaming Clubs (Hours and Charges) (Scotland) Amendment Regulations 1993 (S.I. 1993/1040) Reconstitution of the Bedfordshire and River Ivel Internal Drainage Board Order 1993 (S.I. 1993/1041) Glan Conwy-Conwy Morfa Trunk Road (A547) (Previously known as and forming part of The Chester—Bangor Trunk Road (A55)) Detrunking Order 1993 (S.I. 1993/1057) International Finance Corporation (1991 General Capital Increase) Order 1993 (S.I. 1993/1059) Asian Development Bank (Fifth Replenishment of the Asian Development Fund and Second Regularized Replenishment of the Technical Assistance Special Fund) Order 1993 (S.I. 1993/1060) Banking Appeal Tribunal (Scottish Appeals) Amendment Regulations 1993 (S.I. 1993/1061) Financial Assistance for Environmental Purposes Order 1993 (S.I. 1993/1062) A43 Trunk Road (Silverstone Bypass and Slip Roads) Order 1993 (S.I.
=== Available forms === Two arsenic-containing stereoisomers exist in a 3:1 molar ratio. Since melarsoprol is insoluble in water, dosage occurs via a 3.6% propylene glycol intravenous injection. To avoid the risk of injection site reactions, melarsoprol must be given slowly. Melarsoprol used for the treatment of African trypanosomiasis with CNS involvement is given under a complicated dosing schedule. The dosing schedule for children and adults is 2–3.6 mg/kg/day intravenously for three days, then repeated every seven days for a total of three series. To monitor for relapse, follow-up is recommended every six months for at least two years.
Sources: en.wikipedia.org
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.
Trifluoroacetate and acetate are common in lyophilized peptide preparations. They contribute to the mass of the powder without contributing to the peptide itself. This shifts the true content and can affect results in biological assays.
Hydrolysis and oxidation are the primary pathways. Alkaline conditions accelerate hydrolytic cleavage of the chain. Oxidation most often involves susceptible residues, producing products that appear as earlier or later peaks in chromatographic analysis.
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.